Health Condition 1: G938- Other specified disorders of brain
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Histological diagnosis of diffuse glioma. Radionecrosis on imaging with new neurological symptoms/ worsening of prior deficits (Stratum A) or without new symptoms (Stratum B). Karnofsky Performance Scale (KPS) = 50.
Exclusion criteria
Exclusion criteria: No tissue diagnosis. KPS Disease progression Contraindications to corticosteroids. Altered mental status with deficits in understanding or inability to consent to the study. Brainstem glioma Indeterminate for radionecrosis vs disease progression Prior treatment with bevacizumab (either for disease progression or radionecrosis)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rates (clinical-radiological) at 1 month with the use of CHL.Timepoint: 1 month post treatment with chlorophyllin | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical-radiological response rates at 3 months Biological response rates using functional imaging (PET & MRI) Survival Analysis (Progression-Free Survival and Overall Survival) EORTC QOL C -30 and BN-20 questionnaire at baseline, 1-month, and at 3-month follow-ups NANO scale score QTWIST scoreTimepoint: at 3mnths | — |
Countries
India
Contacts
Tata Memorial Hospital